• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Azura Ophthalmics raises $16m for meibomian gland dysfunction therapy

October 10, 2017 By Sarah Faulkner

Biotech Azura Ophthalmics said today that it closed a $16 million Series B round led by a syndicate of OrbiMed, TPG Biotech and Brandon Capital’s Medical Research Commercialization Fund. Existing investor Ganot Capital also participated in the round.

The investment is slated to support Azura’s development of a drug for a leading cause of dry eye disease – meibomian gland dysfunction.

The Israel-based company’s chief executive, Marc Gleeson, spent 14 years at Allergan (NYSE:AGN) as VP of global marketing for ophthalmology. The company’s latest personnel change involved recruiting another former Allergan employee – Charles Bosworth, who now serves as Azura’s CMO.

“Our leadership team has had tremendous success, not only in ophthalmology start-ups, but also specifically in dry eye drug development and commercialization. The appointment of Charles Bosworth brings the necessary clinical and dry eye experience to our innovative approach to MGD. We are pleased to have such an accomplished healthcare leader join the team,” Gleeson said in prepared remarks.

“With the support of our syndicate of investors and Ganot Capital we’re able to significantly expand our clinical efforts and attract the right talent and experience to execute our vision of providing treatment to those suffering from this disease.”

“This latest round of financing validates the strength of our team’s accomplishments to date and will fuel Azura’s unique and innovative approach to treating dry eye,” co-founder Eugene de Juan added. “We are now poised to further develop our clinical studies to demonstrate the drug’s efficacy and seek regulatory clearance.”

The company’s MGD therapy is moving into a Phase IIa trial, after it demonstrated efficacy in a clinical proof-of-concept trial.

See the best minds in medtech live at DeviceTalks West, Dec. 11–12 in Orange County, Calif.

Filed Under: Featured, Funding Roundup, Optical/Ophthalmic Tagged With: Allergan, azuraophthalmics

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS